ABSTRACT
To compare the frequency and clinical significance of familial and de novo chromosomal inversions during prenatal diagnosis. This was a retrospective study of inversions diagnosed prenatally in an Asian population by applying conventional GTG-banding to amniocyte cultures. Data from 2005 to 2019 were extracted from a single-center laboratory database. The types, frequencies, and inheritance patterns of multiple inversions were analyzed. Pericentric variant inversions of chromosome 9 or Y were excluded. In total, 56 (0.27%) fetuses with inversions were identified in the 15-year database of 21,120 confirmative diagnostic procedures. Pericentric and paracentric inversions accounted for 62.5% (35/56) and 37.5% of the inversions, respectively. Familial inversions accounted for nearly 90% of cases, and de novo mutation was identified in two pericentric and two paracentric cases. Inversions were most frequently identified on chromosomes 1 and 2 (16.1% of all inversions), followed by chromosomes 6, 7, and 10 (8.9% of all cases). The indications for invasive testing were as follows: advanced maternal age (67.3%), abnormal ultrasound findings (2.1%), abnormal serum aneuploidy screening (20.4%), and other indications (10.2%). The mode of inheritance was available for 67.9% of cases (38/56), with 89.5% of inversions being inherited (34/38). A slight preponderance of inheritance in female fetuses was observed. Three patients with inherited inversions opted for termination (two had severe central nervous system lesions and one had thalassemia major). Gestation continued for 53 fetuses, who exhibited no structural defects at birth or significant developmental problems a year after birth. Our study indicates that approximately 90% of prenatally diagnosed inversions involve familial inheritance, are spreading, and behave like founder effect mutations in this isolated population on an island. This finding can help to alleviate anxiety during prenatal counseling, which further underscores the importance of parental chromosomal analysis, further genetic studies, and appropriate counseling in cases where a nonfamilial inversion is diagnosed.
Subject(s)
Chromosome Inversion/statistics & numerical data , Congenital Abnormalities/epidemiology , Congenital Abnormalities/genetics , Pregnancy Outcome/epidemiology , Pregnancy Trimester, Second/genetics , Prenatal Diagnosis/statistics & numerical data , Amniocentesis , Aneuploidy , Asian People/genetics , Congenital Abnormalities/diagnosis , Databases, Genetic , Female , Fetal Development/genetics , Humans , Male , Pregnancy , Pregnancy Outcome/genetics , Retrospective StudiesABSTRACT
The immune system of skin develops in stages in mice. However, the developmental dynamics of immune cells in human skin remains elusive. Here, we perform transcriptome profiling of CD45+ hematopoietic cells in human fetal skin at an estimated gestational age of 10-17 weeks by single-cell RNA sequencing. A total of 13 immune cell types are identified. Skin macrophages show dynamic heterogeneity over the course of skin development. A major shift in lymphoid cell developmental states occurs from the first to the second trimester that implies an in situ differentiation process. Gene expression analysis reveals a typical developmental program in immune cells in accordance with their functional maturation, possibly involving metabolic reprogramming. Finally, we identify transcription factors (TFs) that potentially regulate cellular transitions by comparing TFs and TF target gene networks. These findings provide detailed insight into how the immune system of the human skin is established during development.
Subject(s)
Fetus/cytology , Gene Expression Profiling , Single-Cell Analysis , Skin/embryology , Skin/immunology , Cell Differentiation , Cell Lineage/genetics , Female , Gene Expression Regulation , Gestational Age , Humans , Lymphocytes/cytology , Lymphocytes/metabolism , Macrophages/cytology , Macrophages/metabolism , Myeloid Cells/cytology , Myeloid Cells/metabolism , Pregnancy , Pregnancy Trimester, Second/genetics , Skin/cytology , Time Factors , Transcription Factors/metabolism , TranscriptomeABSTRACT
AIMS: To investigate whether second trimester maternal serum screening (2TMSS) biomarkers are associated with cerebral palsy (CP) and identify CP characteristics associated with abnormal biomarker levels. METHOD: In this retrospective case-control data linkage study, we linked mothers of 129 singleton CP cases from a population register to their 2TMSS records and selected 10 singleton pregnancy controls per case (n = 1290). We compared mean and abnormal levels of alpha-fetoprotein (AFP), beta subunit of human chorionic gonadotrophin (ß-hCG), unconjugated estriol (uE3), and inhibin between cases and controls and within CP subgroups. RESULTS: Compared to control pregnancies, CP pregnancies had higher mean levels of AFP (1.10 vs. 1.01 multiple of the population median [MoM], p = 0.01) and inhibin (1.10 vs. 0.98 MoM, p ≤ 0.01). CP pregnancies were 2.5 times more likely to be associated with high levels of AFP (OR 2.52 [95% confidence interval [CI] 1.30, 4.65]; p < 0.01) and 2.6 times for inhibin (OR 2.63 [95% CI 1.37, 4.77]; p < 0.01), and 6.8 times when AFP and inhibin were both elevated (OR 6.75 [95% CI 2.41, 18.94]; p < 0.01). In CP cases, high AFP and high inhibin levels were associated with preterm birth and low birthweight. INTERPRETATION: Abnormal second-trimester biomarker levels suggest abnormal placentation plays a role in the causal pathway of some CP cases.
Subject(s)
Biomarkers/analysis , Cerebral Palsy/diagnosis , Mothers/statistics & numerical data , Pregnancy Trimester, Second/blood , Adult , Analysis of Variance , Biomarkers/blood , Case-Control Studies , Cerebral Palsy/epidemiology , Cerebral Palsy/genetics , Female , Humans , Pregnancy , Pregnancy Trimester, Second/genetics , Prenatal Diagnosis/methods , Prenatal Diagnosis/standards , Prenatal Diagnosis/statistics & numerical data , Retrospective Studies , Victoria/epidemiologyABSTRACT
OBJECTIVE: To investigate the genetic etiology of skeletal dysplasia in highly selected fetuses during the first and second trimesters using deep phenotyping and exome sequencing (ES). METHOD: Fetuses with short femurs were identified using the established prenatal diagnostic approach. A multidisciplinary team reviewed fetal phenotypic information (prenatal ultrasound findings, fetal postmortem, and radiographs) in a cohort of highly selected fetuses with skeletal dysplasia during the first and second trimesters. The affected families underwent multiplatform genetic tests. RESULTS: Of the 27 affected fetuses, 21 (77.8%) had pathogenic or potential pathogenic variations in the following genes: COL1A1, FGFR3, COL2A1, COL1A2, FLNB, DYNC2LI1, and TRIP11. Two fetuses had compound heterozygous mutations in DYNC2LI1 and TRIP11, respectively, and the other 19 carried de novo autosomal dominant variants. Novel variants were identified in COL1A1, COL2A1, COL1A2, DYNC2LI1, and TRIP11 in 11 fetuses. We also included the first description of the phenotype of odontochondrodysplasia in a prenatal setting. CONCLUSIONS: ES or panel sequencing offers a high diagnostic yield for fetal skeletal dysplasia during the first and second trimesters. Comprehensive and complete phenotypic information is indispensable for genetic analysis and the expansion of genotype-phenotype correlations in fetal skeletal abnormalities.
Subject(s)
Dentinogenesis Imperfecta/diagnosis , Exome Sequencing/standards , Osteochondrodysplasias/diagnosis , Phenotype , Adult , Dentinogenesis Imperfecta/genetics , Female , Fetus , Gestational Age , Humans , Osteochondrodysplasias/genetics , Pregnancy , Pregnancy Trimester, First/genetics , Pregnancy Trimester, Second/genetics , Ultrasonography, Prenatal/methods , Ultrasonography, Prenatal/standards , Ultrasonography, Prenatal/statistics & numerical data , Exome Sequencing/methods , Exome Sequencing/statistics & numerical dataABSTRACT
OBJECTIVE: To compare the second-trimester plasma cell-free (PCF) transcriptome of women who delivered at term with that of women with spontaneous preterm birth (sPTB) at or before 32 weeks of gestation and identify/validate PCF RNA markers present by 16 weeks of gestation. DESIGN: Prospective case-control study. SETTING: Academic tertiary care centre. POPULATION: Pregnant women with known outcomes prospectively sampled. METHODS: PCF RNAs extracted from women at 22-24 weeks of gestation (five sPTB up to 32 weeks and five at term) were hybridised to gene expression arrays. Differentially regulated RNAs for sPTB up to 32 weeks were initially selected based on P value compared with control (P < 0.01) and fold change (≥1.5×). Potential markers were then reordered by narrowness of distribution. Final marker selection was made by searching the Metacore™ database to determine whether the PCF RNAs interacted with a reported set of myometrial Preterm Initiator genes. RNAs were confirmed by quantitative reverse transcription polymerase chain reaction and tested in a second group of 40 women: 20 with sPTB up to 32 weeks (mean gestation 26.5 weeks, standard deviation ±2.6 weeks), 20 with spontaneous term delivery (40.1 ± 0.9 weeks) sampled at 16-19+5 weeks of gestation. MAIN OUTCOME MEASURE: Identification of PCF RNAs predictive of sPTB up to 32 weeks. RESULTS: Two hundred and ninety-seven PCR RNAs were differentially expressed in sPTB up to 32 weeks of gestation. Further selection retained 99 RNAs (86 mRNAs and 13 microRNAs) and five of these interacted in silica with seven Preterm Initiator genes. Four of five RNAs were confirmed and tested on the validation group. The expression of each confirmed PCF RNA was significantly higher in sPTB up to 32 weeks of gestation. In vitro study of the four mRNAs revealed higher expression in placentas of women with sPTB up to 32 weeks and the potential to interfere with myometrial quiescence. CONCLUSIONS: The PCF RNA markers are highly associated with sPTB up to 32 weeks by 16 weeks of gestation. TWEETABLE ABSTRACT: Women destined for spontaneous preterm birth can be identified by 16 weeks of gestation with a panel of maternal plasma RNAs.
Subject(s)
Maternal Serum Screening Tests , Pregnancy Trimester, Second/blood , Premature Birth/diagnosis , Premature Birth/genetics , RNA/blood , Adult , Biomarkers/blood , Case-Control Studies , Female , Humans , Infant, Newborn , MicroRNAs/blood , Predictive Value of Tests , Pregnancy , Pregnancy Trimester, Second/genetics , Prospective Studies , RNA, Messenger/blood , TranscriptomeABSTRACT
Elevation of total cell-free DNA (cfDNA) in patients with preeclampsia is well-known; however, whether this change precedes the onset of symptoms remains inconclusive. Here, we conducted a nested case-control study to determine the elevation of cfDNA levels in women who subsequently developed preeclampsia. Methylated HYP2 (m-HYP2) levels were determined in 68 blood samples collected from women with hypertensive disorders of pregnancy, along with 136 control samples, using real-time quantitative PCR. The measured m-HYP2 levels were converted to multiples of the median (MoM) values for correction of maternal characteristics. The m-HYP2 levels and MoM values in patients with preeclampsia were significantly higher than in controls during the third trimester (P < 0.001, both), whereas those for women who subsequently developed preeclampsia did not differ during the second trimester. However, when patients with preeclampsia were divided based on the onset-time of preeclampsia or 10th percentile birth weight, both values were significantly higher in women who subsequently developed early-onset preeclampsia (P < 0.05, both) and preeclampsia with small-for-gestational-age (SGA) neonate (P < 0.01, both) than controls. These results suggested that total cfDNA levels could be used to predict early-onset preeclampsia or preeclampsia with SGA neonate.
Subject(s)
Cell-Free Nucleic Acids/genetics , Epigenesis, Genetic , Fetal Growth Retardation/diagnosis , Peptide Initiation Factors/genetics , Pre-Eclampsia/diagnosis , RNA-Binding Proteins/genetics , Adult , Biomarkers/blood , Case-Control Studies , Cell-Free Nucleic Acids/blood , DNA Methylation , Female , Fetal Growth Retardation/genetics , Humans , Infant, Newborn , Infant, Small for Gestational Age , Parturition , Peptide Initiation Factors/blood , Pre-Eclampsia/blood , Pre-Eclampsia/genetics , Pregnancy , Pregnancy Trimester, Second/blood , Pregnancy Trimester, Second/genetics , Pregnancy Trimester, Third/blood , Pregnancy Trimester, Third/genetics , RNA-Binding Proteins/blood , Eukaryotic Translation Initiation Factor 5AABSTRACT
CONTEXT: Insulin-like growth factor (IGF) signaling is crucial for sex differentiation and development of Leydig and Sertoli cells in fetal mice testes. No such information is available for human embryonic and fetal testes and ovaries. OBJECTIVE: To investigate presence and activity of the IGF signaling system during human embryonic and fetal ovarian and testicular development. DESIGN: Human embryonic and fetal gonads were obtained following legal terminations of pregnancies. Gene expression was assessed by microarray and qPCR transcript analyses. Proteins of the IGF system components were detected with immunohistochemistry and immunofluorescence analyses. Specimens were included from 2010 to 2017. SETTING: University Hospital. PATIENTS/PARTICIPANTS: Ovaries and testes from a total of 124 human embryos and fetuses aged 5 to 17 postconception weeks were obtained from healthy women aged 16 to 47 years resident in Denmark or Scotland. MAIN OUTCOME MEASURES: Gene expression analysis using microarray was performed in 46 specimens and qPCR analysis in 56 specimens, both sexes included. Protein analysis included 22 specimens (11 ovaries, 11 testes). RESULTS: IGF system members were detected in embryonic and fetal testes and ovaries, both at gene transcript and protein level. A higher expression of IGF regulators was detected in testes than ovaries, with a preferred localization to Leydig cells. CONCLUSIONS: These data indicate that the IGF system is active during very early gestation, when it may have a regulatory role in Leydig cells.
Subject(s)
Gonads , Insulin-Like Growth Factor Binding Proteins/genetics , Pregnancy Trimester, First/genetics , Pregnancy Trimester, Second/genetics , Receptors, Somatomedin/genetics , Somatomedins/genetics , Adolescent , Adult , Embryo, Mammalian , Female , Fetus/metabolism , Fetus/pathology , Gene Expression Profiling , Gene Expression Regulation, Developmental , Gestational Age , Gonads/embryology , Gonads/metabolism , Gonads/pathology , Humans , Insulin-Like Growth Factor Binding Proteins/metabolism , Male , Microarray Analysis , Middle Aged , Pregnancy , Pregnancy Trimester, First/metabolism , Pregnancy Trimester, Second/metabolism , Receptors, Somatomedin/metabolism , Signal Transduction/genetics , Somatomedins/metabolism , Young AdultABSTRACT
OBJECTIVE: The present prospective follow-up study aimed to evaluate the effects of KCNMB2 gene polymorphisms on ritodrine efficacy and adverse drug events (ADEs) in patients with preterm labor. METHODS: A total of 163 preterm labor patients were included in this single-center study. Nine single nucleotide polymorphisms (SNPs) in the KCNMB2 gene (rs10936979, rs7624046, rs7429015, rs7625907, rs6443559, rs9839376, rs9637454, rs11918114, and rs1382045) were assessed. The primary endpoint was time to delivery, and the secondary endpoint was ritodrine-induced ADEs. RESULTS: Patients with variant homozygotes of two SNPs (rs7624046 and rs9839376), which were in linkage disequilibrium, showed 2.06 [95% confidence interval (CI), 1.14-3.73] and 2.68 (95% CI, 1.16-6.20) times the hazard of time to delivery compared to wild-type allele carriers, respectively. Among demographic characteristics, gestational age at start of drug therapy and modified Bishop score were significant factors for time to delivery. Regarding safety outcomes, patients with variant homozygotes of rs7625907 had fewer ADEs compared to those with other genotypes (odds ratio, 0.32; 95% CI, 0.13-0.83). CONCLUSION: This pharmacogenomic study suggests that ritodrine efficacy and ADEs are associated with KCNMB2 gene polymorphisms in patients with preterm labor.
Subject(s)
Large-Conductance Calcium-Activated Potassium Channel beta Subunits/genetics , Obstetric Labor, Premature/drug therapy , Polymorphism, Single Nucleotide , Ritodrine/administration & dosage , Tocolytic Agents/administration & dosage , Adult , Female , Gestational Age , Humans , Linkage Disequilibrium , Logistic Models , Maternal Age , Obstetric Labor, Premature/genetics , Pregnancy , Pregnancy Trimester, Second/genetics , Pregnancy Trimester, Third/genetics , Prospective Studies , Ritodrine/adverse effects , Tocolytic Agents/adverse effectsABSTRACT
Unexplained recurrent spontaneous abortion (URSA) is defined as the loss of two or more consecutive pregnancies before the 20th week of gestation with normal findings on routine screening tests. Our understanding of the cellular and molecular pathogenesis of URSA is still far from complete. Noncoding RNAs (ncRNAs) play a pivotal role in transcription and expression. The functions of ncRNAs may also improve understanding of URSA pathogenesis. Because of their stability in the circulatory system and at the maternal-fetal interface, it may be possible to use ncRNAs as biomarkers for certain disease states. Here, we provide a narrative review of the current state of knowledge about ncRNAs associated with URSA. The possibility of developing a diagnostic tool using ncRNAs is discussed. The underlying mechanisms of how ncRNAs may lead to the onset of URSA are explored in this review.
Subject(s)
Abortion, Habitual/genetics , Pregnancy Trimester, Second/genetics , RNA, Untranslated/genetics , Abortion, Habitual/diagnosis , Case-Control Studies , Female , Genetic Markers , Genetic Predisposition to Disease , Humans , PregnancyABSTRACT
INTRODUCTION: Obesity is increasing among the pregnant population. Leptin has an important role in the regulation of energy balance and hunger. The aim of this study was to investigate the association between maternal leptin levels with maternal obesity, gestational weight gain (GWG), single nucleotide polymorphisms (SNPs) within the leptin gene, and the age-adjusted birth weight of the child. MATERIAL AND METHODS: Maternal leptin levels (n = 740) and SNPs (n = 504) were analyzed in blood samples taken within the Uppsala Biobank of Pregnant women at pregnancy weeks 16-19. RESULTS: Maternal leptin levels differed significantly between body mass index (BMI) groups. Normal weight women had the lowest median leptin levels and levels increased with each BMI group. Leptin SNP genotype was not associated with leptin levels or BMI. There was also no association between maternal leptin levels and age-adjusted birth weight of the child except for a negative association between leptin levels and birth weight in the morbid obese group. DISCUSSION/CONCLUSION: Maternal BMI was identified as the best positive explanatory factor for maternal leptin levels. Leptin was a strong positive explanatory factor for GWG. Birth weight of children of uncomplicated pregnancies was, however, dependent on maternal height, BMI, GWG, and parity but not leptin levels, except for in morbid obese women where a negative association between maternal leptin levels and birth weight was found. We speculate that this indicates altered placental function, not manifested in pregnancy complication. We conclude that maternal leptin levels do not affect the birth weight of the child more than BMI, GWG, and parity.
Subject(s)
Birth Weight/genetics , Body Mass Index , Gestational Age , Gestational Weight Gain/genetics , Leptin , Polymorphism, Single Nucleotide , Pregnancy Trimester, Second , Adult , Female , Humans , Infant, Newborn , Leptin/blood , Leptin/genetics , Pregnancy , Pregnancy Complications/blood , Pregnancy Complications/genetics , Pregnancy Trimester, Second/blood , Pregnancy Trimester, Second/geneticsABSTRACT
PURPOSE: Non-aneuploid recurrent pregnancy loss (RPL) affects approximately 100,000 pregnancies worldwide annually. Exome sequencing (ES) may help uncover the genetic etiology of RPL and, more generally, pregnancy loss as a whole. Previous studies have attempted to predict the genes that, when disrupted, may cause human embryonic lethality. However, predictions by these early studies rarely point to the same genes. Case reports of pathogenic variants identified in RPL cases offer another clue. We evaluated known genetic etiologies of RPL identified by ES. METHODS: We gathered primary research articles from PubMed and Embase involving case reports of RPL reporting variants identified by ES. Two authors independently reviewed all articles for eligibility and extracted data based on predetermined criteria. Preliminary and amended analysis isolated 380 articles; 15 met all inclusion criteria. RESULTS: These 15 articles described 74 families with 279 reported RPLs with 34 candidate pathogenic variants in 19 genes (NOP14, FOXP3, APAF1, CASP9, CHRNA1, NLRP5, MMP10, FGA, FLT1, EPAS1, IDO2, STIL, DYNC2H1, IFT122, PADI6, CAPS, MUSK, NLRP2, NLRP7) and 26 variants of unknown significance in 25 genes. These genes cluster in four essential pathways: (1) gene expression, (2) embryonic development, (3) mitosis and cell cycle progression, and (4) inflammation and immunity. CONCLUSIONS: For future studies of RPL, we recommend trio-based ES in cases with normal parental karyotypes. In vitro fertilization with preimplantation genetic diagnosis can be pursued if causative variants are found. Utilization of other sequencing technologies in concert with ES should improve understanding of the causes of early embryonic lethality in humans.
Subject(s)
Abortion, Habitual/diagnosis , Abortion, Habitual/genetics , Exome Sequencing/methods , Genes, Essential , Pregnancy Trimester, First/genetics , Pregnancy Trimester, Second/genetics , Female , Humans , PregnancySubject(s)
Cell-Free Nucleic Acids/economics , Cell-Free Nucleic Acids/genetics , Down Syndrome/genetics , Prenatal Diagnosis/standards , Biomarkers/blood , Cell-Free Nucleic Acids/blood , Down Syndrome/diagnosis , Female , Humans , Mass Screening/economics , Mass Screening/methods , Pregnancy , Pregnancy Trimester, First/blood , Pregnancy Trimester, First/genetics , Pregnancy Trimester, Second/blood , Pregnancy Trimester, Second/geneticsABSTRACT
AIM: The purpose of the present study is to evaluate and understand the association of global and MTHFR gene specific methylation in preeclampsia and recurrent miscarriages in light of MTHFR C677T polymorphism. METHODS: The subjects comprised of recurrent miscarriage cases, their gestation matched controls, preeclampsia cases and matched controls. A set of women at full term were also recruited. Fasting blood sample (~5â¯ml) was drawn from all the participants followed by DNA extraction, global DNA methylation and MTHFR gene specific methylation. MTHFR C677T polymorphism was analysed by PCR followed by RFLP. RESULTS HIGHER: Global DNA methylation at maternal front (pâ¯=â¯0.04) and hypomethylation of MTHFR gene at fetal front (pâ¯=â¯0.001) might be a characteristic of preeclampsia. Recurrent miscarriage cases were having significantly (pâ¯=â¯0.002) hyper MTHFR gene specific methylation as compared to controls. Women carrying CT genotype were found to be having significantly (pâ¯=â¯0.001) higher global DNA methylation in PE cases and MTHFR gene specific methylation (pâ¯=â¯0.005) in RM cases. Intergenerational analysis revealed similar patterns of global DNA methylation and MTHFR gene specific methylation among both PE and RM cases at maternal and fetal fronts. CONCLUSION: The study highlights the importance of global DNA methylation in Preeclampsia and MTHFR gene specific methylation in recurrent miscarriages. MTHFR C677T gene polymorphism in association with global and gene specific methylation seem to play a pivotal role in PE and RM respectively.
Subject(s)
Abortion, Habitual/genetics , DNA Methylation , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Pre-Eclampsia/genetics , Adult , Case-Control Studies , Female , Genetic Association Studies , Genetic Predisposition to Disease , Homocystinuria/complications , Homocystinuria/genetics , Humans , India , Methylenetetrahydrofolate Reductase (NADPH2)/deficiency , Muscle Spasticity/complications , Muscle Spasticity/genetics , Polymorphism, Restriction Fragment Length , Polymorphism, Single Nucleotide , Pre-Eclampsia/diagnosis , Pregnancy , Pregnancy Trimester, Second/genetics , Pregnancy Trimester, Third/genetics , Psychotic Disorders/complications , Psychotic Disorders/geneticsABSTRACT
BACKGROUND: Maternal blood folate concentrations during pregnancy have been previously linked with DNA methylation patterns, but this has been done predominantly through observational studies. We showed recently in an epigenetic analysis of the first randomized controlled trial (RCT) of folic acid supplementation specifically in the second and third trimesters (the EpiFASSTT trial) that methylation at some imprinted genes was altered in cord blood samples in response to treatment. Here, we report on epigenome-wide screening using the Illumina EPIC array (~ 850,000 sites) in these same samples (n = 86). RESULTS: The top-ranked differentially methylated promoter region (DMR) showed a gain in methylation with folic acid (FA) and was located upstream of the imprint regulator ZFP57. Differences in methylation in cord blood between placebo and folic acid treatment groups at this DMR were verified using pyrosequencing. The DMR also gains methylation in maternal blood in response to FA supplementation. We also found evidence of differential methylation at this region in an independent RCT cohort, the AFAST trial. By altering methylation at this region in two model systems in vitro, we further demonstrated that it was associated with ZFP57 transcription levels. CONCLUSIONS: These results strengthen the link between folic acid supplementation during later pregnancy and epigenetic changes and identify a novel mechanism for regulation of ZFP57. This trial was registered 15 May 2013 at www.isrctn.com as ISRCTN19917787.
Subject(s)
DNA Methylation/drug effects , DNA-Binding Proteins/genetics , Folic Acid/administration & dosage , Pregnancy Trimester, Second/genetics , Pregnancy Trimester, Third/genetics , Transcription Factors/genetics , Adult , Double Bind Interaction , Female , Folic Acid/blood , Genomic Imprinting , HCT116 Cells , Humans , Pregnancy , Pregnancy Trimester, Second/blood , Pregnancy Trimester, Second/drug effects , Pregnancy Trimester, Third/blood , Pregnancy Trimester, Third/drug effects , Repressor Proteins , Sequence Analysis, DNAABSTRACT
BACKGROUND/AIM: The study aimed to examine whether resistin is present in second trimester amniotic fluid from pregnancies with trisomy 18 and 13 and evaluate its concentration in comparison with euploid pregnancies. PATIENTS AND METHODS: The study included 37 women who underwent amniocentesis. Eleven fetuses had trisomy 18, 3 had trisomy 13, while 23 had a normal karyotype. RESULTS: Resistin was detected in all cases. The mean level of resistin in trisomy 18 was statistically significantly lower compared to euploid controls. Resistin levels in all abnormal cases were below its median concentration in euploid controls. ROC analysis showed very good prognostic value for both trisomies. CONCLUSION: Resistin is a constituent of mid-trimester amniotic fluid of pregnancies with trisomies 13 and 18, exhibiting lower levels than those in euploid fetuses. The reduced levels of resistin in amniotic fluid may be associated with early changes in metabolic pathways and immunoinflammatory responses.
Subject(s)
Amniotic Fluid/chemistry , Pregnancy Trimester, Second/genetics , Resistin/genetics , Trisomy 18 Syndrome/genetics , Adult , Chromosomes, Human, Pair 13/genetics , Female , Gestational Age , Humans , Pregnancy , Resistin/chemistry , Trisomy 18 Syndrome/pathologyABSTRACT
OBJECTIVE: To evaluate the reasons for nonreportable cell-free DNA (cfDNA) results in noninvasive prenatal testing (NIPT), we retrospectively studied maternal characteristics and other details associated with the results. METHODS: A multicenter retrospective cohort study in pregnant women undergoing NIPT by massively parallel sequencing (MPS) with failed cfDNA tests was performed between April 2013 and March 2017. The women's data and MPS results were analyzed in terms of maternal characteristics, test performance, fetal fraction (FF), z scores, anticoagulation therapy, and other details of the nonreportable cases. RESULTS: Overall, 110 (0.32%) of 34 626 pregnant women had nonreportable cfDNA test results after an initial blood sampling; 22 (20.0%) cases had a low FF (<4%), and 18 (16.4%) cases including those with a maternal malignancy, were found to have altered genomic profile. Approximately half of the cases with nonreportable results had borderline z score. Among the women with nonreportable results because of altered genomic profile, the success rate of retesting using a second blood sampling was relatively low (25.0%-33.3%). Thirteen (11.8%) of the women with nonreportable results had required hypodermic heparin injection. CONCLUSIONS: The classification of nonreportable results using cfDNA analysis is important to provide women with precise information and to reduce anxiety during pregnancy.
Subject(s)
Genetic Testing/methods , High-Throughput Nucleotide Sequencing , Prenatal Diagnosis/methods , Research Design , Trisomy/diagnosis , Adult , False Negative Reactions , Female , High-Throughput Nucleotide Sequencing/methods , High-Throughput Nucleotide Sequencing/standards , High-Throughput Nucleotide Sequencing/statistics & numerical data , Humans , Predictive Value of Tests , Pregnancy , Pregnancy Trimester, First/blood , Pregnancy Trimester, First/genetics , Pregnancy Trimester, Second/blood , Pregnancy Trimester, Second/genetics , Reproducibility of Results , Research Design/standards , Research Design/statistics & numerical data , Retrospective Studies , Risk Factors , Trisomy/geneticsABSTRACT
The placenta is crucial for a successful pregnancy and the health of both the fetus and the pregnant woman. However, how the human trophoblast lineage is regulated, including the categorization of the placental cell subtypes is poorly understood. Here we performed single-cell RNA sequencing (RNA-seq) on sorted placental cells from first- and second-trimester human placentas. New subtypes of cells of the known cytotrophoblast cells (CTBs), extravillous trophoblast cells (EVTs), Hofbauer cells, and mesenchymal stromal cells were identified and cell-type-specific gene signatures were defined. Functionally, this study revealed many previously unknown functions of the human placenta. Notably, 102 polypeptide hormone genes were found to be expressed by various subtypes of placental cells, which suggests a complex and significant role of these hormones in regulating fetal growth and adaptations of maternal physiology to pregnancy. These results document human placental trophoblast differentiation at single-cell resolution and thus advance our understanding of human placentation during the early stage of pregnancy.
Subject(s)
Peptide Hormones/genetics , Placenta/cytology , Placentation/genetics , Trophoblasts/metabolism , Base Sequence , Cell Differentiation , Female , Gene Expression , Humans , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Pregnancy , Pregnancy Trimester, First/genetics , Pregnancy Trimester, First/metabolism , Pregnancy Trimester, Second/genetics , Pregnancy Trimester, Second/metabolism , Sequence Analysis, RNA/methods , Single-Cell Analysis/methodsABSTRACT
OBJECTIVE: Maternal plasma is a source of circulating placental nucleic acids. In this study, we validated previous observations on abnormal levels of circulating messenger RNA (mRNA) for the tenascin-X gene in pregnancies with ventricular septal defects in the second trimester of pregnancy. METHODS: This was a bicentric retrospective study conducted from March 2016 to July 2017. Real-time polymerase chain reaction was used to identify abnormally expressed genes, comparing ten women carrying a euploid fetus with ventricular septal defects to 30 controls at 19-24 weeks of gestation. The univariable analysis was used to determine whether the mean mRNA for the tenascin-X gene values would differ from the expected values for the controls. RESULTS: mRNA for tenascin-X gene values was higher in ventricular septal defects, 4.38 ± 3.01 versus 1.00 ± 0.80. The result was still significant even after adjustment for gestational age. CONCLUSIONS: These data confirm previous studies on the specific association of mRNA species and type of congenital heart defect and confirm that ventricular septal defects are associated with abnormal mRNA for the tenascin-X gene. The positive predictive value of this molecular marker in the general population should be assessed through prospective studies.
Subject(s)
Heart Septal Defects, Ventricular/blood , Heart Septal Defects, Ventricular/genetics , Pregnancy Trimester, Second/blood , Pregnancy Trimester, Second/genetics , RNA, Messenger/blood , Tenascin/genetics , Adult , Demography , Female , Humans , PregnancyABSTRACT
OBJECTIVE: To investigate the role of maternal serum placenta growth factor (PlGF) and quadruple test parameters in predicting the risk of small for gestational age (SGA) infants of mothers without preeclampsia. MATERIALS AND METHODS: We prospectively enrolled 300 pregnant patients who underwent blood sampling at 15-18 weeks gestation and followed them until delivery. Cases with SGA neonate delivery (n = 100) were compared with matched AGA neonate controls (n = 200). The plasma PlGF and quadruple markers were measured by enzyme-linked immunosorbent assay. The results were analyzed with Mann-Whitney U tests, and regression analysis was used to develop a model for the prediction of SGA. RESULTS: Women who delivered SGA neonates had decreased levels of PlGF (median 0.71 MoM versus 0.7 MoM; p < 0.01), hCG (median 0.97 MoM versus 1.06 MoM; p = 0.046) and uE3 (median 0.92 MoM versus 1.04 MoM) compared to the AGA group. AFP, hCG and inhibin-A levels did not differ significantly. A PlGF concentration <0.37 MoM had a sensitivity of 28.0% (95% CI: 19.5-37.9) and a specificity of 89.5% (95% CI: 84.4-93.4) for the prediction of SGA neonates without PE. CONCLUSION: SGA neonates in the absence of PE could potentially be identified at 15-18 weeks of pregnancy.
Subject(s)
Infant, Small for Gestational Age/blood , Maternal Serum Screening Tests/methods , Placenta Growth Factor/blood , Pregnancy Trimester, Second/blood , Adult , Aneuploidy , Biomarkers/blood , Female , Gestational Age , Humans , Predictive Value of Tests , Pregnancy , Pregnancy Trimester, Second/genetics , Prospective Studies , Regression Analysis , Sensitivity and Specificity , Statistics, NonparametricABSTRACT
The placenta relies on phenotypes that are characteristic of cancer to successfully implant the embryo in the uterus during early pregnancy. Notably, it has to invade its host tissues, promote angiogenesis-while surviving hypoxia-, and escape the immune system. Similarities in DNA methylation patterns between the placenta and cancers suggest that common epigenetic mechanisms may be involved in regulating these behaviors. We show here that megabase-scale patterns of hypomethylation distinguish first from third trimester chorionic villi in the placenta, and that these patterns mirror those that distinguish many tumors from corresponding normal tissues. We confirmed these findings in villous cytotrophoblasts isolated from the placenta and identified a time window at the end of the first trimester, when these cells come into contact with maternal blood, as the likely time period for the methylome alterations. Furthermore, the large genomic regions affected by these patterns of hypomethylation encompass genes involved in pathways related to epithelial-mesenchymal transition, immune response, and inflammation. Analyses of expression profiles corresponding to genes in these hypomethylated regions in colon adenocarcinoma tumors point to networks of differentially expressed genes previously implicated in carcinogenesis and placentogenesis, where nuclear factor kappa B is a key hub. Taken together, our results suggest the existence of epigenetic switches involving large-scale changes of methylation in the placenta during pregnancy and in tumors during neoplastic transformation. The characterization of such epigenetic switches might lead to the identification of biomarkers and drug targets in oncology as well as in obstetrics and gynecology.